Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with β-thalassemia major poorly compliant to subcutaneous injections

Pediatric Hematology and Oncology

Volumn 21, Issue 5, 2004, Pages 453-460

  Wali, Yasser A ^a   Taqi, Aqila ^a   Deghaidi, Akram ^b  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Children; Deferrioxamine; High dose; Thalassemia

Indexed keywords

DEFEROXAMINE; FERRITIN; IRON;

ADOLESCENT; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; INJECTION PAIN; INTRAVENOUS CATHETER; IRON CHELATION; IRON URINE LEVEL; KIDNEY FUNCTION; LIVER FUNCTION; MALE; PATIENT COMPLIANCE; PRURITUS; SCHOOL CHILD; SIDE EFFECT; THALASSEMIA MAJOR; TREATMENT OUTCOME;

ADOLESCENT; BETA-THALASSEMIA; CHILD; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; IRON; IRON CHELATING AGENTS; MALE; PATIENT COMPLIANCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 3042842872     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010490457259     Document Type: Article

References (15)

1. Al-Riyami A, Ebrahim GJ. Genetic blood disorders survey in the Sultanate of Oman. J Trop Pediatr. 2003;49(Suppl 1):1-20.
2. Nienhuis AW. Thalassemia major: molecular and clinical aspects. Ann Inter Med. 1979;91:883-892.
3. Walman IJ. Transfusion therapy in Cooly's anemia: growth and health as related to hemoglobin levels. Ann NY Acad Sci. 1964;119:736-742.
4. Giradina PJ, Grady RW. Chelation therapy in β-thalassemia: an optimistic update. Semin Hematol. 2001;38:360-366.
5. Ceci A, Felisi M, De Sanctis V, De Mattia D. Pharmacotherapy of iron overload in thalassemic patients. Expert Opin Pharmacother. 2003;4:1763-1774.
6. Taher A, Sheikh-Taha M, Koussa S, Inati A, Mourad F. Comparison between deferrioxamine and deferiprone (LI) in iron-loaded thalassemic patients. Eur J Hematol. 2001;67:30-34.
7. Cohen AR, Mizanin RN, Schwartz E, Rapid removal of excessive iron with daily high dose intravenous chelation therapy. J Pediatr. 1989;115:151-155.
8. Cohen A, Schwartz E. Iron chelation therapy with deferrioxamine in Cooly's anemia. J Pediatr. 1978;92:643-647.
9. Hagege I, Becker A, Kerdafrec T, Kaufer A, Girot A. Long term administration of IV high dose deferrioxamine in thalassemic patients. Eur J Hematol. 2001;67:230-236.
10. Davis BA, Porter JB. Long term outcome of continuous 24-hour deferrioxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229-1236.
11. Gritchton RR, Roman F, Roland F. Iron mobilization from ferritin by chelating agents. J Inorg Biochem. 1980;13:305-309.
12. Worwood M, Crogg SJ, Jacob SA, McLaren C, Ricketts C, Economidore J. Binding of serum ferritin to concanavalin A: patients with homozygous (β-thalassemia and transfusional iron overload. Br J Haematol. 1980;46:409-415.
13. Porter JB, Abeysinghe RD, Marshall L, Hider PC. Kinetics of removal and reappearance of nontransferrin bound plasma iron with deferrioxamine therapy. Blood. 1996;88:705-709.
14. Pippard MJ, Callender ST, Finch CA. Ferrioxamine excretion in iron-loaded man. Blood. 1982;60:288-294.
15. Olivieri NF, Berriman AM, Ttler B. Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferrioxamine. Am J Hematol, 1992;41:61-66.